BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor


10/14/2009 7:49:53 AM

Bookmark and Share

CARLSBAD, Calif., Oct. 13 /PRNewswire/ -- Luminous Medical, Inc. announced today that it has reached agreement with a major supplier of electrochemical sensors for exclusive rights to incorporate its glucose sensor into Luminous' automated blood glucose monitor. Luminous is developing its monitor to enable clinicians to control hyperglycemia in critical care patients around the world.

Previously, Luminous was planning to use a sensing technology based on near-infrared spectrometry. "More than a year ago we realized that it was going to be difficult to gain FDA clearance for any novel glucose technology for use in the critical care environment," said Richard Thompson, president and CEO of Luminous Medical. "Our new approach uses standard, calibratable glucose oxidase chemistry with which the agency is very familiar."

Luminous has already incorporated the glucose oxidase sensing technology into its design and is preparing for pivotal clinical trials and a 510k application in 2010. "We were fortunate that we could modify our product to accept the new sensing technology," said Bill Patterson, Vice President of R&D. "The sensor is already being used in a product that has been cleared by the FDA to measure glucose in the ICU, which makes our development process straightforward."

Glucose oxidase electrochemistry has been used to measure glucose with near laboratory accuracy in point of care devices for many years. The FDA has recently expressed concern about the use of test strip based glucose meters that are not cleared to manage glucose in hospitalized patients. The Luminous product is being designed to automate the process of glucose monitoring while simultaneously raising the bar for measurement accuracy at the point of care.

About Luminous Medical, Inc.:

Luminous is developing an automated blood glucose monitor to address the strong clinical demand for glycemic control. Multiple clinical studies have demonstrated significant morbidity and mortality benefits from controlling glucose levels in critical care patients. As a result, clinicians have rapidly adopted glycemic control procedures but struggle with inadequate and time consuming manual methods. The Luminous monitor is being designed to automate these glycemic control procedures.

Luminous will be displaying its automated blood glucose monitor at the Society of Critical Care Medicine's Post-Congress Conference to be held in Key West, Florida from January 13th - January 15th, 2010. The product has not been cleared for use by the FDA. More information is available at www.luminousmedical.com.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->